Analysts Set Expectations for RNTX Q1 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX) – Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Rein Therapeutics in a research report issued on Thursday, April 2nd. HC Wainwright analyst B. Folkes anticipates that the company will post earnings of ($0.49) per share for the quarter. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Rein Therapeutics’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS and FY2030 earnings at $0.43 EPS.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Thursday, March 26th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.12).

RNTX has been the topic of several other research reports. cut Rein Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 21st. Citigroup cut Rein Therapeutics to a “hold” rating in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 14th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Rein Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.00.

Rein Therapeutics Stock Performance

NASDAQ:RNTX opened at $1.21 on Friday. The business’s fifty day moving average price is $1.24 and its 200 day moving average price is $1.30. Rein Therapeutics has a 1-year low of $1.02 and a 1-year high of $2.40. The firm has a market capitalization of $33.93 million, a price-to-earnings ratio of -0.62 and a beta of 1.40.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RNTX. Gleason Group Inc. bought a new stake in shares of Rein Therapeutics during the third quarter worth $26,000. Susquehanna International Group LLP bought a new position in Rein Therapeutics in the third quarter valued at about $35,000. HRT Financial LP acquired a new stake in Rein Therapeutics in the fourth quarter worth about $38,000. Northwestern Mutual Wealth Management Co. bought a new stake in Rein Therapeutics during the 2nd quarter worth about $68,000. Finally, Jane Street Group LLC bought a new stake in Rein Therapeutics during the 4th quarter worth about $72,000. 90.89% of the stock is currently owned by institutional investors.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.